Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Clinical Trial to Evaluate Stem Cell Treatment of Massive Knee Cartilage Injury

Andrews Institute for Orthopaedics & Sports Medicine and the Andrews Research & Education Foundation are facilitating a randomized, multi-center Phase II U.S. FDA-observed clinical trial evaluating use of a patient's own stem cells to regenerate knee cartilage.

This is reportedly the first time that stem cells will be evaluated in a clinical trial for the ability to regenerate cartilage in massive knee cartilage injuries. The 6-year study may end early if results indicate statistical significance.

The study is partially funded by the Malaysian government and seeks to replicate outcomes from clinical treatments currently available to patients in Malaysia using a cartilage regeneration technology developed by Dr. Khay-Yong Saw, an orthopaedic surgeon who practices at Kuala Lumpur Sports Medicine Center (KLSMC) in Kuala Lumpur, Malaysia.

“The whole concept of regenerating cartilage is totally different from what’s being used now to treat damaged cartilage,” said Dr. Saw. “We are hoping this study will help the FDA evaluate the safety and the effectiveness of this clinical application."

Source: Andrews Institute for Orthopaedics & Sports Medicine

Andrews Institute

Dr. Adam Anz (right) and Dr. Khay-Yong Saw (left)
at the Andrews Institute Regenerative Medicine Center,
which will serve as the location for the clinical trial.

4 COMMENTS

Security code
Refresh